

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137390 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
A61K 31/713 (2006.01) A61K 31/712 (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:

PCT/US2024/061179

(22) International Filing Date:

19 December 2024 (19.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/612,531 20 December 2023 (20.12.2023) US
63/634,860 16 April 2024 (16.04.2024) US
63/683,214 14 August 2024 (14.08.2024) US

(71) Applicant: **ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US).

(72) Inventors: **NGAI, Michelle**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, Wisconsin 53719 (US). **MAJEWSKI, Mark**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **DING, Zhi-Ming**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **GLEBOCKA, Agnieszka**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **PEI, Tao**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, Wisconsin 53719 (US). **HAMILTON, James**; Arrowhead Pharmaceuticals, Inc., 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US). **SHEKHTMAN, Grigoriy**; Arrowhead Pharmaceuticals, Inc., 177 East Colorado Boulevard, Suite 700, Pasadena, California 91105 (US).

(74) Agent: **CHEN, Meibo**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, MADISON, WI 53719 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2025/137390 A1

(54) Title: RNAI AGENTS FOR INHIBITING EXPRESSION OF ACTIVIN RECEPTOR-LIKE KINASE 7 (ALK7), COMPOSITIONS THEREOF, AND METHODS OF USE

(57) Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Activin Receptor-Like Kinase 7 (ALK7) gene. The ALK7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an ALK7 gene. Pharmaceutical compositions that include one or more ALK7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described ALK7 RNAi agents to adipose tissue, *in vivo*, provides for inhibition of ALK7 gene expression and a reduction in ALK7 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including obesity, diabetes, or insulin resistance.